Video summary

New Game-Changing Lenses for Cataract Surgery in 2026

Main summary

Key takeaways

Science and Nature

Scientific concepts, discoveries, and nature/biomedical phenomena

Accommodation and its loss in aging

  • In youth, the eye’s ciliary muscle changes the lens shape via zonules, enabling focusing from far to near (accommodation).
  • With age, people develop presbyopia (typically starting around age 40), losing this focusing ability.
  • After cataract surgery, the natural lens is replaced by a rigid intraocular lens (IOL), so accommodation does not return.

Current post-cataract vision solutions and trade-offs

  • Multifocal / extended depth of focus (EDOF) IOLs
    • Provide a broader focus range by splitting light (often using concentric ring optics).
    • Downsides: reduced sharpness/contrast and frequent halos/starbursts around lights.
  • Monovision
    • Sets one eye for distance and the other for near.
    • Downsides: can reduce depth perception and may cause dizziness/nausea, plus poor tolerance of inter-eye prescription differences.

“Holy grail” goal

A next-generation IOL that restores a full range of vision (near, intermediate, distance) without sacrificing image quality (contrast/sharpness) or causing major optical side effects.

Lenses discussed (latest/most promising), and how they work

OmniView IOL (accommodating; clinical trial phase)

  • Core design principle: uses small eye movements to mimic natural accommodation.
  • Mechanism
    • Modular design with:
      • a fixed power front optic
      • a shape-changing base filled with fluid
    • Ciliary muscle movement alters the fluid-filled base shape, changing focusing power.
  • Reported clinical data
    • Dr. Steven Dell presented 2-year results (at ASCRS 2025) for 19 patients / 29 eyes.
    • Outcomes reported:
      • strong uncorrected near/intermediate/distance
      • average visual acuity ~20/20 (intermediate to distance)
      • average visual acuity ~20/25 (near) for both eyes
      • contrast sensitivity comparable to monofocal IOLs
      • stable refraction over 24 months.

Lumina lens (CE-marked; available in Europe)

  • Mechanism
    • Two optics slide over each other in response to accommodation-like movement, shifting optical power for distance↔near focusing.
  • Key concerns/limitations noted
    • Implant position: designed for placement in the ciliary sulcus (not the capsular bag).
      • Risk highlighted: possible UGH syndrome (uveitis + increased intraocular pressure/glaucoma + hyphema/bleeding).
    • Customization requirement
      • Must be perfectly sized for the patient’s sulcus dimensions.
      • Requires custom ordering (size + power + astigmatism), described as taking about ~60 days, raising scalability/lead-time concerns.

Adaptiv Lens IOL (preclinical/early clinical stage; planned human trials)

  • Material innovation
    • Founder LeAnne Condon, working with Duke University researchers, developed a soft, flexible polymer that can:
      • withstand long-term implantation
      • deform like the natural lens (squishy/flexible but durable)
  • Mechanism
    • Lens shape and focusing power change with eye-muscle movement to provide vision at near, intermediate, and far.
  • Development status
    • Company raised $17.5 million (investors).
    • Completed preclinical testing and planned first-in-human trials in 2026, with ongoing path toward FDA approval.

Juvene lens (accommodating; clinical trials; reported longer-term outcomes)

  • Mechanism
    • Base haptic with a fixed-power lens placed in the capsular bag.
    • A shape-changing fluid lens “docks” into the base.
    • Ciliary muscle changes fluid lens shape → shifts focusing power.
  • Reported study results
    • A 3-year study reporting safety/efficacy:
      • Uncorrected vision when implanted in one eye:
        • ~20/18 distance
        • ~20/25 intermediate
        • ~20/35 near
      • better results when implanted in both eyes
    • Stability: results maintained for over 3 years.
  • Observed/claimed side-effect profile
    • Reported no significant loss of contrast/sharpness
    • no significant halos/glares
  • Regulatory stage
    • Still described as in clinical trials preparing for FDA submission (as of 2025).

Fluid Vision IOL (accommodating; in studies)

  • Mechanism
    • Hollow central optic
    • Fluid-filled haptics at the periphery
    • Capsule movement due to ciliary muscle contraction pushes fluid into the central optic
    • Fluid redistribution changes optic shape → focusing power changes
  • Research status
    • Mentioned multi-center studies including Orion study.
    • Preliminary results described as encouraging for distance/intermediate/near acuity.

Jellycat IOL (accommodating; early implantation reported)

  • Mechanism
    • Stable posterior portion
    • Flexible front portion changes shape
    • Inserted in the capsular bag with eight springy connectors (“actuators”)
    • Capsule movement (from ciliary muscle activity) deforms the front portion → changes focusing power
  • Research status
    • Already implanted in 10 patients in El Salvador
    • Additional safety/efficacy studies underway.

Historical cautionary example: Crystal lens (context for new designs)

Background

  • Described as the first and last FDA-approved accommodating lens (approved in 2003).
  • Used flexible haptics to mimic accommodation.

Problems observed after real-world use

  • Insufficient range of vision (near/intermediate/distance)
    • Some surgeons used mini-monovision to compensate.
  • Lens instability after capsule scarring
    • Flexible haptics did not maintain lens position/tilt as effectively
    • Led to poor vision requiring laser or additional surgery in reported cases.

Lesson driving newer designs

New IOLs also use flexible components for pseudo-accommodation, but must balance flexibility with:

  • stability
  • safety
  • adequate vision range without unacceptable optical artifacts.

Organizations/events and sources mentioned

  • American Academy of Ophthalmology meeting (in Orlando, Florida) — described as a place where companies made announcements.
  • American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting 2025 — where OmniView results were presented.
  • FDA — referenced for approval history and future approval pathways.

Researchers or sources featured (as named in the subtitles)

  • Dr. Steven Dell
  • LeAnne Condon
  • Duke University (researchers; not individually named)

Original video